MLH1 methylation followed by MSI-high (MSI-H) is known to be associated with a good prognosis in patients with sporadic CRC (27–29), while BRAF mutation is one of the genetic markers of a shorter survival time (4,30). This evidence concerns the gene MLH1 and colorectal carcinoma.